Quantcast

Latest Mesalazine Stories

2008-10-07 09:00:14

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that 1.5 g mesalamine granules once-daily maintained remission versus placebo in ulcerative colitis (UC) patients who switched from another 5-ASA product (78 percent of relapse-free subjects vs. 59 percent (P less than 0.001)). These patients also had a greater probability of remaining relapse free after six months compared to placebo (77 percent vs. 50 percent (Pless than0.001) cumulative relapse-free probability)(1). Mesalamine...

2008-10-06 12:00:43

Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue. Commercial Insight: Inflammatory Bowel Disease - Convenience and compliance drive market success http://www.reportlinker.com/p095770/Commercial-Insight-Inflammatory-Bowel-Disease---Convenience-and-compliance-drive-market-success.html Introduction Several product launches and indication expansion caused substantial sales growth in the seven major...

2008-10-06 09:00:09

PHILADELPHIA, Oct. 6 /PRNewswire-FirstCall/ -- Shire plc , the global specialty biopharmaceutical company, announced the results from a multidisciplinary analysis of in vitro and in vivo data of LIALDA(R) (mesalamine) versus Asacol(R) (mesalamine) that investigated factors including transit and disintegration of tablets along with tablet coating thickness that may affect a consistent release of 5-aminosalicylate acid (5-ASA) in both therapies. This analysis will be presented at The American...

2008-08-13 09:01:16

WALTHAM, Mass., Aug. 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that robust annual five percent growth through 2017 in the ulcerative colitis drug market will be driven by strong uptake of Abbott/Eisai's Humira, Centocor/Schering-Plough/Mitsubishi Tanabe Pharma/Janssen's golimumab and Bristol-Myers Squibb's Orencia, following the expected approvals and launches of these three biologic agents...

2008-06-26 06:02:08

By Spinks, Julian THE BASICS Differentiating ulcerative colitis from other bowel conditions can be difficult, says Dr Julian Spinks Ulcerative colitis (UC) is a chronic inflammatory disease of the colon with a prevalence of 35-100 per 100,000. The age of onset has two peaks, one in the second to fourth decades and the other in the sixth and seventh decades of life. Women are 30 per cent more likely to develop UC. The aetiology is not yet fully understood but it is considered to be...

2008-06-17 12:00:09

BASINGSTOKE, UK and PHILADELPHIA, US June 17 /PRNewswire-FirstCall/ -- Shire Limited , the global specialty biopharmaceutical company, today announced the publication of data from a randomized, long-term safety and tolerability study (study 303) of ulcerative colitis (UC) drug Lialda(TM) (mesalamine). The primary endpoints of this study were to assess the safety and tolerability of Lialda in mild-to-moderate UC patients over 12 months. Data were published in the July issue of Gut, the...

2008-06-05 03:00:00

By Bone, Kerry Crohn's disease is a chronic autoimmune disease of unknown cause, characterized by inflammation of the gut wall triggered by an attack from the immune system. The immune system, which normally attacks invading viruses or bacteria, is somehow stimulated to attack the body's own tissue (in this case, the gut wall). A recent survey found there has been no change in the results from conventional treatment for Crohn's (such as drugs) in the past 40 years.1 But there is hope. Recent...

2007-12-31 12:00:26

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) seeking approval to market granulated mesalamine. Salix believes this application will be subject to a 10-month review period. "This application is based upon results from two large, multicenter, 6-month, double-blind, randomized, placebo-controlled studies. These studies demonstrated a statistically significantly greater...

2007-03-23 06:00:11

By Rezania, Dorna; Ouban, Abderrhman; Marcet, Jorge; Kelley, Scott; Coppola, Domenico The association between cytomegalovirus infection and inflammatory bowel disease challenges both the clinician and the pathologist to establish the correct diagnosis and to prescribe the most appropriate form of therapy. To understand this association the authors report three patients who presented with signs and symptoms mimicking reactivated inflammatory bowel disease who responded poorly to aggressive...

2007-03-19 12:00:19

BASINGSTOKE, England and PHILADELPHIA, March 19 /PRNewswire-FirstCall/ -- Shire plc today announced the availability of LIALDA(TM) (mesalamine) with MMX(TM) Technology, indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC), a type of inflammatory bowel disease. LIALDA is the first and only FDA-approved once daily oral formulation of mesalamine. The U.S. Food and Drug Administration (FDA) approved LIALDA on January 16, 2007. LIALDA is...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related